Spl-sunitinib-northstar-12.5 mg Label (Spl Sunitinib Northstar 12.5 mg Label.jpg.jpg)
This text is not readable.*
Sunitinib Malate Capsule
Product Images NDC 16714-679
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sunitinib Malate (NDC 16714-679). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Spl-sunitinib-northstar-25 mg Label (Spl Sunitinib Northstar 25 mg Label)
Spl-sunitinib-northstar-37.5 mg Label (Spl Sunitinib Northstar 37.5 mg Label.jpg.jpg)
Spl-sunitinib-northstar-50 mg Label (Spl Sunitinib Northstar 50 mg Label)
Spl-sunitinib-northstar-figure-1 (Spl Sunitinib Northstar Figure 1)
This is a clinical trial study comparing the effect of Sunitinib versus Placebo on Time to Tumor Progression. The study included 207 participants given Sunitinib and 105 given Placebo. Median time to tumor progression was 27.3 weeks for Sunitinib versus 6.4 weeks for Placebo. Hazard ratio was 0.33 (95% CI 0.23 to 0.47) with a significant p-value of <0.0001. The time frame for the study was in weeks.*
Spl-sunitinib-northstar-figure-2 (Spl Sunitinib Northstar Figure 2)
The text is providing a comparison of Sumitinib and IFN-a drugs for Progression Free Survival Probability (%). It includes the number of subjects in each group, their median weeks, hazard ratio, and CI values. The text also shows a graph representing the percentage of survival probability over time in both groups.*
Spl-sunitinib-northstar-figure-4 (Spl Sunitinib Northstar Figure 4)
This text is a statistical analysis of a medical study comparing the effectiveness of the drug Sunitinib versus a placebo in terms of progression-free survival in patients. It includes survival probabilities, hazard ratios, and median survival times for both groups, as well as a graph showing the number of subjects at risk over time.*
Spl-sunitinib-northstar-molecular Structure (Spl Sunitinib Northstar Molecular Structure)
Spl-sunitinib-northstar-figure 3 (Spl Sunitinib Northstar Figure 3)
This is a graph with Disease-Free Survival Probability (%) on the y-axis and Time (Years) on the x-axis, with hazard ratio equal to 0.76. The graph compares two groups, Sunitinib and Placebo, based on the number of subjects at risk over a duration of 10 years. The P-value is 0.03.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
